Dr. Chang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3939 J St
Ste 106
Sacramento, CA 95819Phone+1 916-454-4861Fax+1 916-454-3603
Education & Training
Johns Hopkins UniversityResidency, Ophthalmology, 2003 - 2005
Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 2002 - 2003
Columbia University Vagelos College of Physicians and SurgeonsClass of 2002
Certifications & Licensure
CA State Medical License 2008 - 2025
MD State Medical License 2006 - 2008
PA State Medical License 2002 - 2003- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Publications & Presentations
PubMed
- 3 citationsVision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.Carl J Danzig, Arshad M Khanani, Peter K Kaiser, Margaret A Chang, Jaclyn L Kovach
Ophthalmology. Retina. 2024-11-01 - Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff
Ophthalmology. Retina. 2024-08-30 - 1 citationsExtended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad
Journal of Vitreoretinal Diseases. 2024-08-22
Press Mentions
Effect of Initial Management with Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityMay 1st, 2019
Surgical Interventions for Retinal Vascular Diseases: A Deep Dive into the DataSeptember 7th, 2023- New Geographic Atrophy Drugs: The Good, the Bad, and the UnknownMay 14th, 2024
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
